Ignite Creation Date:
2025-12-26 @ 10:19 PM
Ignite Modification Date:
2025-12-26 @ 10:19 PM
Study NCT ID:
NCT00603512
Status:
COMPLETED
Last Update Posted:
2013-01-25
First Post:
2008-01-17
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001172', 'term': 'Arthritis, Rheumatoid'}], 'ancestors': [{'id': 'D001168', 'term': 'Arthritis'}, {'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D012216', 'term': 'Rheumatic Diseases'}, {'id': 'D003240', 'term': 'Connective Tissue Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C479163', 'term': 'tofacitinib'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrials.gov_Inquiries@pfizer.com', 'phone': '1-800-718-1021', 'title': 'Pfizer ClinicalTrials.gov Call Center', 'organization': 'Pfizer, Inc.'}, 'certainAgreement': {'otherDetails': 'Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'description': 'The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.', 'eventGroups': [{'id': 'EG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.', 'otherNumAtRisk': 28, 'otherNumAffected': 14, 'seriousNumAtRisk': 28, 'seriousNumAffected': 1}, {'id': 'EG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.', 'otherNumAtRisk': 27, 'otherNumAffected': 16, 'seriousNumAtRisk': 27, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.', 'otherNumAtRisk': 27, 'otherNumAffected': 19, 'seriousNumAtRisk': 27, 'seriousNumAffected': 1}, {'id': 'EG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.', 'otherNumAtRisk': 26, 'otherNumAffected': 19, 'seriousNumAtRisk': 26, 'seriousNumAffected': 2}, {'id': 'EG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.', 'otherNumAtRisk': 28, 'otherNumAffected': 11, 'seriousNumAtRisk': 28, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Cataract', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Conjunctivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Dry eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Eyelid pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Vision blurred', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Gastric mucosal lesion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Gastrooesophageal reflux disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Haematochezia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Paraesthesia oral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Stomach discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Malaise', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Acute tonsillitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Cystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Dermatitis infected', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Enterocolitis viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Erysipelas', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Gastroenteritis viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Localised infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Paronychia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Peritonsillitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Pharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Tinea pedis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Viral upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Vulvovaginal candidiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Vulvovaginitis trichomonal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Foot fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Joint sprain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Spinal compression fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Thermal burn', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Apolipoprotein A-I increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Blood alkaline phosphatase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Blood cholesterol increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Blood creatine phosphokinase MM increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Blood triglycerides increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Epstein-Barr virus test positive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Haemoglobin decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Low density lipoprotein increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Lymphocyte count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Lymphocyte percentage decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Viral DNA test positive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'White blood cell count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Hypercholesterolaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Intervertebral disc protrusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Joint swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Monarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Muscle fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Muscle tightness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Musculoskeletal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Synovial cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Cervical myelopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Hypoaesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Sciatica', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Calculus ureteric', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Cystitis-like symptom', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Enuresis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Urinary incontinence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Breast pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Dysmenorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Metrorrhagia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Pleural effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Upper respiratory tract inflammation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Dermatitis contact', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 2}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Haemorrhage subcutaneous', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Hyperhidrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Purpura', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Skin ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Stomatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}], 'seriousEvents': [{'term': 'Cardiac failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Femur fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Foot deformity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 27, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 28, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v11.1'}], 'frequencyThreshold': '2'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '64.3', 'groupId': 'OG000'}, {'value': '77.8', 'groupId': 'OG001'}, {'value': '96.3', 'groupId': 'OG002'}, {'value': '80.8', 'groupId': 'OG003'}, {'value': '14.3', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 12', 'description': 'ACR20 response: greater than or equal to (\\>=) 20 percent (%) improvement in tender joint count (TJC); \\>= 20% improvement in swollen joint count (SJC); and \\>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP).', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) included all randomized participants who received at least 1 dose of study medication. Missing values were imputed using Last observation carried forward (LOCF) method.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 1', 'categories': [{'measurements': [{'value': '28.57', 'groupId': 'OG000'}, {'value': '14.81', 'groupId': 'OG001'}, {'value': '29.63', 'groupId': 'OG002'}, {'value': '38.46', 'groupId': 'OG003'}, {'value': '3.57', 'groupId': 'OG004'}]}]}, {'title': 'Week 2', 'categories': [{'measurements': [{'value': '32.14', 'groupId': 'OG000'}, {'value': '40.74', 'groupId': 'OG001'}, {'value': '62.96', 'groupId': 'OG002'}, {'value': '50.00', 'groupId': 'OG003'}, {'value': '10.71', 'groupId': 'OG004'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '50.00', 'groupId': 'OG000'}, {'value': '55.56', 'groupId': 'OG001'}, {'value': '88.89', 'groupId': 'OG002'}, {'value': '76.92', 'groupId': 'OG003'}, {'value': '10.71', 'groupId': 'OG004'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '67.86', 'groupId': 'OG000'}, {'value': '66.67', 'groupId': 'OG001'}, {'value': '96.30', 'groupId': 'OG002'}, {'value': '80.77', 'groupId': 'OG003'}, {'value': '21.43', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 1, 2, 4, 8', 'description': 'ACR20 response: \\>= 20% improvement in TJC; \\>= 20% improvement in SJC; and \\>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study medication. Missing values were imputed using LOCF method.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 1', 'categories': [{'measurements': [{'value': '7.14', 'groupId': 'OG000'}, {'value': '3.70', 'groupId': 'OG001'}, {'value': '0.00', 'groupId': 'OG002'}, {'value': '7.69', 'groupId': 'OG003'}, {'value': '0.00', 'groupId': 'OG004'}]}]}, {'title': 'Week 2', 'categories': [{'measurements': [{'value': '7.14', 'groupId': 'OG000'}, {'value': '7.41', 'groupId': 'OG001'}, {'value': '25.93', 'groupId': 'OG002'}, {'value': '26.92', 'groupId': 'OG003'}, {'value': '0.00', 'groupId': 'OG004'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '10.71', 'groupId': 'OG000'}, {'value': '22.22', 'groupId': 'OG001'}, {'value': '29.63', 'groupId': 'OG002'}, {'value': '34.62', 'groupId': 'OG003'}, {'value': '3.57', 'groupId': 'OG004'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '28.57', 'groupId': 'OG000'}, {'value': '29.63', 'groupId': 'OG001'}, {'value': '70.37', 'groupId': 'OG002'}, {'value': '50.00', 'groupId': 'OG003'}, {'value': '7.14', 'groupId': 'OG004'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '32.14', 'groupId': 'OG000'}, {'value': '44.44', 'groupId': 'OG001'}, {'value': '81.48', 'groupId': 'OG002'}, {'value': '57.69', 'groupId': 'OG003'}, {'value': '14.29', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 1, 2, 4, 8, 12/End of Treatment (EOT)', 'description': 'ACR50 response: \\>= 50% improvement in tender or swollen joint counts and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study medication. Missing values were imputed using LOCF method.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 1', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'groupId': 'OG001'}, {'value': '0.00', 'groupId': 'OG002'}, {'value': '3.85', 'groupId': 'OG003'}, {'value': '0.00', 'groupId': 'OG004'}]}]}, {'title': 'Week 2', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000'}, {'value': '3.70', 'groupId': 'OG001'}, {'value': '11.11', 'groupId': 'OG002'}, {'value': '3.85', 'groupId': 'OG003'}, {'value': '0.00', 'groupId': 'OG004'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '3.57', 'groupId': 'OG000'}, {'value': '7.41', 'groupId': 'OG001'}, {'value': '14.81', 'groupId': 'OG002'}, {'value': '7.69', 'groupId': 'OG003'}, {'value': '0.00', 'groupId': 'OG004'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '3.57', 'groupId': 'OG000'}, {'value': '7.41', 'groupId': 'OG001'}, {'value': '33.33', 'groupId': 'OG002'}, {'value': '26.92', 'groupId': 'OG003'}, {'value': '3.57', 'groupId': 'OG004'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '7.14', 'groupId': 'OG000'}, {'value': '14.81', 'groupId': 'OG001'}, {'value': '33.33', 'groupId': 'OG002'}, {'value': '34.62', 'groupId': 'OG003'}, {'value': '3.57', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 1, 2, 4, 8, 12/EOT', 'description': 'ACR70 response: \\>= 70% improvement in tender or swollen joint counts and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study medication. Missing values were imputed using LOCF method.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 1', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'groupId': 'OG001'}, {'value': '0.00', 'groupId': 'OG002'}, {'value': '0.00', 'groupId': 'OG003'}, {'value': '0.00', 'groupId': 'OG004'}]}]}, {'title': 'Week 2', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'groupId': 'OG001'}, {'value': '0.00', 'groupId': 'OG002'}, {'value': '3.85', 'groupId': 'OG003'}, {'value': '0.00', 'groupId': 'OG004'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000'}, {'value': '0.00', 'groupId': 'OG001'}, {'value': '3.70', 'groupId': 'OG002'}, {'value': '0.00', 'groupId': 'OG003'}, {'value': '0.00', 'groupId': 'OG004'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000'}, {'value': '3.70', 'groupId': 'OG001'}, {'value': '7.41', 'groupId': 'OG002'}, {'value': '3.85', 'groupId': 'OG003'}, {'value': '0.00', 'groupId': 'OG004'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000'}, {'value': '11.11', 'groupId': 'OG001'}, {'value': '3.70', 'groupId': 'OG002'}, {'value': '11.54', 'groupId': 'OG003'}, {'value': '0.00', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 1, 2, 4, 8, 12/EOT', 'description': 'ACR90 response: \\>= 90% improvement in tender or swollen joint counts and 90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study medication. Missing values were imputed using LOCF method.'}, {'type': 'SECONDARY', 'title': 'Tender Joint Count (TJC)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Baseline (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '16.36', 'spread': '7.56', 'groupId': 'OG000'}, {'value': '16.22', 'spread': '8.50', 'groupId': 'OG001'}, {'value': '17.81', 'spread': '12.32', 'groupId': 'OG002'}, {'value': '15.42', 'spread': '9.77', 'groupId': 'OG003'}, {'value': '16.36', 'spread': '9.08', 'groupId': 'OG004'}]}]}, {'title': 'Week 1 (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '11.89', 'spread': '7.06', 'groupId': 'OG000'}, {'value': '12.04', 'spread': '10.95', 'groupId': 'OG001'}, {'value': '13.22', 'spread': '14.04', 'groupId': 'OG002'}, {'value': '10.96', 'spread': '11.89', 'groupId': 'OG003'}, {'value': '12.86', 'spread': '9.03', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '11.63', 'spread': '8.72', 'groupId': 'OG000'}, {'value': '9.63', 'spread': '8.72', 'groupId': 'OG001'}, {'value': '9.52', 'spread': '13.12', 'groupId': 'OG002'}, {'value': '8.20', 'spread': '10.91', 'groupId': 'OG003'}, {'value': '11.62', 'spread': '9.43', 'groupId': 'OG004'}]}]}, {'title': 'Week 4 (n=27,26,27,24,25)', 'categories': [{'measurements': [{'value': '10.04', 'spread': '7.64', 'groupId': 'OG000'}, {'value': '7.00', 'spread': '7.61', 'groupId': 'OG001'}, {'value': '8.22', 'spread': '10.48', 'groupId': 'OG002'}, {'value': '5.58', 'spread': '6.35', 'groupId': 'OG003'}, {'value': '13.76', 'spread': '11.30', 'groupId': 'OG004'}]}]}, {'title': 'Week 8 (n=26,25,26,23,24)', 'categories': [{'measurements': [{'value': '6.73', 'spread': '6.80', 'groupId': 'OG000'}, {'value': '5.40', 'spread': '7.64', 'groupId': 'OG001'}, {'value': '5.15', 'spread': '6.49', 'groupId': 'OG002'}, {'value': '3.35', 'spread': '4.71', 'groupId': 'OG003'}, {'value': '11.04', 'spread': '8.38', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '5.92', 'spread': '6.73', 'groupId': 'OG000'}, {'value': '6.38', 'spread': '9.60', 'groupId': 'OG001'}, {'value': '3.63', 'spread': '4.39', 'groupId': 'OG002'}, {'value': '2.71', 'spread': '4.33', 'groupId': 'OG003'}, {'value': '9.96', 'spread': '7.85', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.', 'unitOfMeasure': 'tender joints', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Tender Joint Count (TJC) at Week 1, 2, 4, 8 and 12/EOT', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 1 (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '-4.46', 'spread': '4.80', 'groupId': 'OG000'}, {'value': '-4.19', 'spread': '6.92', 'groupId': 'OG001'}, {'value': '-4.59', 'spread': '5.76', 'groupId': 'OG002'}, {'value': '-4.46', 'spread': '7.61', 'groupId': 'OG003'}, {'value': '-3.50', 'spread': '5.68', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '-4.70', 'spread': '7.37', 'groupId': 'OG000'}, {'value': '-6.59', 'spread': '7.31', 'groupId': 'OG001'}, {'value': '-8.30', 'spread': '6.36', 'groupId': 'OG002'}, {'value': '-6.88', 'spread': '6.09', 'groupId': 'OG003'}, {'value': '-4.54', 'spread': '5.48', 'groupId': 'OG004'}]}]}, {'title': 'Week 4 (n=27,26,27,24,25)', 'categories': [{'measurements': [{'value': '-6.30', 'spread': '8.78', 'groupId': 'OG000'}, {'value': '-9.00', 'spread': '8.94', 'groupId': 'OG001'}, {'value': '-9.59', 'spread': '7.00', 'groupId': 'OG002'}, {'value': '-9.88', 'spread': '7.50', 'groupId': 'OG003'}, {'value': '-2.28', 'spread': '8.38', 'groupId': 'OG004'}]}]}, {'title': 'Week 8 (n=26,25,26,23,24)', 'categories': [{'measurements': [{'value': '-9.42', 'spread': '8.90', 'groupId': 'OG000'}, {'value': '-10.84', 'spread': '9.00', 'groupId': 'OG001'}, {'value': '-12.88', 'spread': '10.77', 'groupId': 'OG002'}, {'value': '-12.09', 'spread': '8.23', 'groupId': 'OG003'}, {'value': '-4.04', 'spread': '7.17', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '-10.23', 'spread': '8.84', 'groupId': 'OG000'}, {'value': '-9.96', 'spread': '10.79', 'groupId': 'OG001'}, {'value': '-14.42', 'spread': '10.43', 'groupId': 'OG002'}, {'value': '-12.71', 'spread': '8.01', 'groupId': 'OG003'}, {'value': '-5.13', 'spread': '7.27', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicates an improvement.', 'unitOfMeasure': 'tender joints', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Swollen Joint Count (SJC)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Baseline (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '13.18', 'spread': '5.63', 'groupId': 'OG000'}, {'value': '15.11', 'spread': '7.92', 'groupId': 'OG001'}, {'value': '15.59', 'spread': '12.41', 'groupId': 'OG002'}, {'value': '15.12', 'spread': '9.96', 'groupId': 'OG003'}, {'value': '13.82', 'spread': '6.27', 'groupId': 'OG004'}]}]}, {'title': 'Week 1 (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '10.07', 'spread': '5.87', 'groupId': 'OG000'}, {'value': '12.62', 'spread': '9.21', 'groupId': 'OG001'}, {'value': '12.70', 'spread': '12.66', 'groupId': 'OG002'}, {'value': '9.73', 'spread': '10.98', 'groupId': 'OG003'}, {'value': '13.18', 'spread': '7.45', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '8.26', 'spread': '4.81', 'groupId': 'OG000'}, {'value': '9.67', 'spread': '6.23', 'groupId': 'OG001'}, {'value': '9.41', 'spread': '11.52', 'groupId': 'OG002'}, {'value': '8.04', 'spread': '11.36', 'groupId': 'OG003'}, {'value': '12.04', 'spread': '6.95', 'groupId': 'OG004'}]}]}, {'title': 'Week 4 (n=27,26,27,24,25)', 'categories': [{'measurements': [{'value': '7.85', 'spread': '6.00', 'groupId': 'OG000'}, {'value': '8.19', 'spread': '6.50', 'groupId': 'OG001'}, {'value': '7.41', 'spread': '9.28', 'groupId': 'OG002'}, {'value': '6.63', 'spread': '7.83', 'groupId': 'OG003'}, {'value': '11.80', 'spread': '7.88', 'groupId': 'OG004'}]}]}, {'title': 'Week 8 (n=26,25,26,23,24)', 'categories': [{'measurements': [{'value': '5.92', 'spread': '4.86', 'groupId': 'OG000'}, {'value': '6.12', 'spread': '5.40', 'groupId': 'OG001'}, {'value': '4.62', 'spread': '4.99', 'groupId': 'OG002'}, {'value': '5.17', 'spread': '6.31', 'groupId': 'OG003'}, {'value': '11.08', 'spread': '8.10', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '5.19', 'spread': '5.87', 'groupId': 'OG000'}, {'value': '5.29', 'spread': '5.43', 'groupId': 'OG001'}, {'value': '3.83', 'spread': '4.24', 'groupId': 'OG002'}, {'value': '4.05', 'spread': '5.98', 'groupId': 'OG003'}, {'value': '11.13', 'spread': '7.12', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.', 'unitOfMeasure': 'swollen joints', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Swollen Joint Count (SJC) at Week 1, 2, 4, 8 and 12/EOT', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 1 (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '-3.11', 'spread': '5.26', 'groupId': 'OG000'}, {'value': '-2.54', 'spread': '6.11', 'groupId': 'OG001'}, {'value': '-2.89', 'spread': '2.81', 'groupId': 'OG002'}, {'value': '-5.38', 'spread': '5.08', 'groupId': 'OG003'}, {'value': '-0.64', 'spread': '3.71', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '-4.74', 'spread': '5.45', 'groupId': 'OG000'}, {'value': '-5.44', 'spread': '6.57', 'groupId': 'OG001'}, {'value': '-6.19', 'spread': '5.02', 'groupId': 'OG002'}, {'value': '-6.84', 'spread': '4.87', 'groupId': 'OG003'}, {'value': '-1.69', 'spread': '3.48', 'groupId': 'OG004'}]}]}, {'title': 'Week 4 (n=27,26,27,24,25)', 'categories': [{'measurements': [{'value': '-5.15', 'spread': '7.25', 'groupId': 'OG000'}, {'value': '-6.69', 'spread': '7.07', 'groupId': 'OG001'}, {'value': '-8.19', 'spread': '5.94', 'groupId': 'OG002'}, {'value': '-8.50', 'spread': '5.16', 'groupId': 'OG003'}, {'value': '-1.68', 'spread': '4.59', 'groupId': 'OG004'}]}]}, {'title': 'Week 8 (n=26,25,26,23,24)', 'categories': [{'measurements': [{'value': '-6.92', 'spread': '6.56', 'groupId': 'OG000'}, {'value': '-8.96', 'spread': '8.25', 'groupId': 'OG001'}, {'value': '-11.35', 'spread': '8.91', 'groupId': 'OG002'}, {'value': '-10.09', 'spread': '6.08', 'groupId': 'OG003'}, {'value': '-2.08', 'spread': '6.55', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '-7.65', 'spread': '7.53', 'groupId': 'OG000'}, {'value': '-9.71', 'spread': '8.16', 'groupId': 'OG001'}, {'value': '-12.58', 'spread': '10.06', 'groupId': 'OG002'}, {'value': '-11.71', 'spread': '6.68', 'groupId': 'OG003'}, {'value': '-2.04', 'spread': '5.77', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement.', 'unitOfMeasure': 'swollen joints', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Patient Assessment of Arthritis Pain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Baseline (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '54.18', 'spread': '23.48', 'groupId': 'OG000'}, {'value': '57.59', 'spread': '20.18', 'groupId': 'OG001'}, {'value': '53.22', 'spread': '25.94', 'groupId': 'OG002'}, {'value': '52.19', 'spread': '24.97', 'groupId': 'OG003'}, {'value': '53.32', 'spread': '23.63', 'groupId': 'OG004'}]}]}, {'title': 'Week 1 (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '45.36', 'spread': '20.32', 'groupId': 'OG000'}, {'value': '43.50', 'spread': '20.69', 'groupId': 'OG001'}, {'value': '40.19', 'spread': '24.03', 'groupId': 'OG002'}, {'value': '37.08', 'spread': '23.38', 'groupId': 'OG003'}, {'value': '49.36', 'spread': '24.42', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '45.11', 'spread': '20.11', 'groupId': 'OG000'}, {'value': '40.52', 'spread': '24.32', 'groupId': 'OG001'}, {'value': '33.19', 'spread': '24.63', 'groupId': 'OG002'}, {'value': '31.40', 'spread': '20.92', 'groupId': 'OG003'}, {'value': '48.58', 'spread': '25.56', 'groupId': 'OG004'}]}]}, {'title': 'Week 4 (n=27,26,27,25,26)', 'categories': [{'measurements': [{'value': '42.44', 'spread': '20.98', 'groupId': 'OG000'}, {'value': '34.88', 'spread': '22.45', 'groupId': 'OG001'}, {'value': '25.19', 'spread': '20.67', 'groupId': 'OG002'}, {'value': '30.46', 'spread': '23.60', 'groupId': 'OG003'}, {'value': '49.72', 'spread': '24.46', 'groupId': 'OG004'}]}]}, {'title': 'Week 8 (n=26,25,27,23,24)', 'categories': [{'measurements': [{'value': '32.65', 'spread': '17.84', 'groupId': 'OG000'}, {'value': '30.04', 'spread': '23.37', 'groupId': 'OG001'}, {'value': '22.59', 'spread': '21.45', 'groupId': 'OG002'}, {'value': '19.43', 'spread': '18.64', 'groupId': 'OG003'}, {'value': '48.88', 'spread': '23.01', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '32.19', 'spread': '17.69', 'groupId': 'OG000'}, {'value': '27.17', 'spread': '21.40', 'groupId': 'OG001'}, {'value': '17.58', 'spread': '17.27', 'groupId': 'OG002'}, {'value': '16.90', 'spread': '20.29', 'groupId': 'OG003'}, {'value': '44.96', 'spread': '25.41', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 = no pain and 100 = most severe pain.', 'unitOfMeasure': 'mm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Patient Assessment of Arthritis Pain at Week 1, 2, 4, 8 and 12/EOT', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 1 (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '-8.82', 'spread': '18.21', 'groupId': 'OG000'}, {'value': '-14.35', 'spread': '16.99', 'groupId': 'OG001'}, {'value': '-13.04', 'spread': '18.78', 'groupId': 'OG002'}, {'value': '-15.12', 'spread': '19.89', 'groupId': 'OG003'}, {'value': '-3.96', 'spread': '14.90', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '-10.41', 'spread': '20.16', 'groupId': 'OG000'}, {'value': '-17.07', 'spread': '25.47', 'groupId': 'OG001'}, {'value': '-20.04', 'spread': '22.04', 'groupId': 'OG002'}, {'value': '-22.44', 'spread': '27.77', 'groupId': 'OG003'}, {'value': '-3.69', 'spread': '10.60', 'groupId': 'OG004'}]}]}, {'title': 'Week 4 (n=27,26,27,24,25)', 'categories': [{'measurements': [{'value': '-13.07', 'spread': '23.22', 'groupId': 'OG000'}, {'value': '-23.35', 'spread': '22.89', 'groupId': 'OG001'}, {'value': '-28.04', 'spread': '23.74', 'groupId': 'OG002'}, {'value': '-24.29', 'spread': '26.28', 'groupId': 'OG003'}, {'value': '-1.00', 'spread': '14.27', 'groupId': 'OG004'}]}]}, {'title': 'Week 8 (n=26,25,27,23,24)', 'categories': [{'measurements': [{'value': '-22.54', 'spread': '26.84', 'groupId': 'OG000'}, {'value': '-28.92', 'spread': '23.46', 'groupId': 'OG001'}, {'value': '-30.63', 'spread': '25.40', 'groupId': 'OG002'}, {'value': '-34.26', 'spread': '26.19', 'groupId': 'OG003'}, {'value': '-2.04', 'spread': '22.66', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '-23.00', 'spread': '25.13', 'groupId': 'OG000'}, {'value': '-32.50', 'spread': '22.75', 'groupId': 'OG001'}, {'value': '-31.38', 'spread': '22.67', 'groupId': 'OG002'}, {'value': '-38.43', 'spread': '28.38', 'groupId': 'OG003'}, {'value': '-5.96', 'spread': '22.61', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 = no pain and 100 = most severe pain.', 'unitOfMeasure': 'mm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Patient Global Assessment (PtGA) of Arthritis', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Baseline (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '58.00', 'spread': '18.27', 'groupId': 'OG000'}, {'value': '60.26', 'spread': '21.79', 'groupId': 'OG001'}, {'value': '58.67', 'spread': '23.63', 'groupId': 'OG002'}, {'value': '52.04', 'spread': '26.27', 'groupId': 'OG003'}, {'value': '53.50', 'spread': '24.04', 'groupId': 'OG004'}]}]}, {'title': 'Week 1 (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '45.89', 'spread': '21.08', 'groupId': 'OG000'}, {'value': '44.27', 'spread': '19.25', 'groupId': 'OG001'}, {'value': '42.56', 'spread': '24.48', 'groupId': 'OG002'}, {'value': '34.73', 'spread': '21.41', 'groupId': 'OG003'}, {'value': '46.54', 'spread': '23.49', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '46.07', 'spread': '22.39', 'groupId': 'OG000'}, {'value': '42.63', 'spread': '23.82', 'groupId': 'OG001'}, {'value': '33.78', 'spread': '25.04', 'groupId': 'OG002'}, {'value': '30.44', 'spread': '20.57', 'groupId': 'OG003'}, {'value': '48.42', 'spread': '25.65', 'groupId': 'OG004'}]}]}, {'title': 'Week 4 (n=27,26,27,24,25)', 'categories': [{'measurements': [{'value': '44.59', 'spread': '22.89', 'groupId': 'OG000'}, {'value': '34.23', 'spread': '21.81', 'groupId': 'OG001'}, {'value': '28.93', 'spread': '21.61', 'groupId': 'OG002'}, {'value': '30.04', 'spread': '22.62', 'groupId': 'OG003'}, {'value': '49.16', 'spread': '25.09', 'groupId': 'OG004'}]}]}, {'title': 'Week 8 (n=26,25,27,23,24)', 'categories': [{'measurements': [{'value': '35.12', 'spread': '17.80', 'groupId': 'OG000'}, {'value': '30.68', 'spread': '24.36', 'groupId': 'OG001'}, {'value': '21.81', 'spread': '22.22', 'groupId': 'OG002'}, {'value': '20.39', 'spread': '20.85', 'groupId': 'OG003'}, {'value': '49.17', 'spread': '22.00', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '31.42', 'spread': '17.08', 'groupId': 'OG000'}, {'value': '24.21', 'spread': '19.82', 'groupId': 'OG001'}, {'value': '17.13', 'spread': '16.00', 'groupId': 'OG002'}, {'value': '16.48', 'spread': '18.62', 'groupId': 'OG003'}, {'value': '43.75', 'spread': '24.60', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 = very well and 100 = very poorly.', 'unitOfMeasure': 'mm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Patient Global Assessment of Arthritis (PtGA) at Week 1, 2, 4, 8 and 12/EOT', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 1 (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '-12.11', 'spread': '17.07', 'groupId': 'OG000'}, {'value': '-16.92', 'spread': '17.48', 'groupId': 'OG001'}, {'value': '-16.11', 'spread': '20.72', 'groupId': 'OG002'}, {'value': '-17.31', 'spread': '20.45', 'groupId': 'OG003'}, {'value': '-6.96', 'spread': '15.78', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '-12.19', 'spread': '18.44', 'groupId': 'OG000'}, {'value': '-17.63', 'spread': '25.30', 'groupId': 'OG001'}, {'value': '-24.89', 'spread': '21.03', 'groupId': 'OG002'}, {'value': '-23.40', 'spread': '28.28', 'groupId': 'OG003'}, {'value': '-3.69', 'spread': '12.29', 'groupId': 'OG004'}]}]}, {'title': 'Week 4 (n=27,26,27,24,25)', 'categories': [{'measurements': [{'value': '-13.67', 'spread': '20.21', 'groupId': 'OG000'}, {'value': '-27.50', 'spread': '21.80', 'groupId': 'OG001'}, {'value': '-29.74', 'spread': '21.90', 'groupId': 'OG002'}, {'value': '-24.50', 'spread': '26.24', 'groupId': 'OG003'}, {'value': '-1.40', 'spread': '14.92', 'groupId': 'OG004'}]}]}, {'title': 'Week 8 (n=26,25,27,23,24)', 'categories': [{'measurements': [{'value': '-22.85', 'spread': '25.79', 'groupId': 'OG000'}, {'value': '-32.04', 'spread': '22.17', 'groupId': 'OG001'}, {'value': '-36.85', 'spread': '22.07', 'groupId': 'OG002'}, {'value': '-33.09', 'spread': '27.70', 'groupId': 'OG003'}, {'value': '-1.46', 'spread': '23.75', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '-26.54', 'spread': '24.18', 'groupId': 'OG000'}, {'value': '-38.00', 'spread': '21.09', 'groupId': 'OG001'}, {'value': '-37.46', 'spread': '19.91', 'groupId': 'OG002'}, {'value': '-38.33', 'spread': '29.46', 'groupId': 'OG003'}, {'value': '-6.88', 'spread': '21.45', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 = very well and 100 = very poorly.', 'unitOfMeasure': 'mm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Physician Global Assessment (PGA) of Arthritis', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Baseline (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '66.00', 'spread': '16.32', 'groupId': 'OG000'}, {'value': '61.44', 'spread': '19.18', 'groupId': 'OG001'}, {'value': '59.37', 'spread': '17.67', 'groupId': 'OG002'}, {'value': '59.04', 'spread': '18.00', 'groupId': 'OG003'}, {'value': '59.39', 'spread': '19.88', 'groupId': 'OG004'}]}]}, {'title': 'Week 1 (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '49.96', 'spread': '17.44', 'groupId': 'OG000'}, {'value': '47.96', 'spread': '19.95', 'groupId': 'OG001'}, {'value': '45.26', 'spread': '21.43', 'groupId': 'OG002'}, {'value': '36.12', 'spread': '19.45', 'groupId': 'OG003'}, {'value': '50.64', 'spread': '22.39', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '44.04', 'spread': '18.74', 'groupId': 'OG000'}, {'value': '42.52', 'spread': '23.78', 'groupId': 'OG001'}, {'value': '34.59', 'spread': '22.64', 'groupId': 'OG002'}, {'value': '28.84', 'spread': '18.90', 'groupId': 'OG003'}, {'value': '44.62', 'spread': '22.26', 'groupId': 'OG004'}]}]}, {'title': 'Week 4 (n=27,26,27,24,25)', 'categories': [{'measurements': [{'value': '41.30', 'spread': '20.94', 'groupId': 'OG000'}, {'value': '33.04', 'spread': '18.66', 'groupId': 'OG001'}, {'value': '24.67', 'spread': '17.67', 'groupId': 'OG002'}, {'value': '23.92', 'spread': '16.60', 'groupId': 'OG003'}, {'value': '47.96', 'spread': '23.20', 'groupId': 'OG004'}]}]}, {'title': 'Week 8 (n=26,25,26,23,24)', 'categories': [{'measurements': [{'value': '29.65', 'spread': '15.94', 'groupId': 'OG000'}, {'value': '26.08', 'spread': '18.70', 'groupId': 'OG001'}, {'value': '17.46', 'spread': '14.83', 'groupId': 'OG002'}, {'value': '16.57', 'spread': '13.62', 'groupId': 'OG003'}, {'value': '40.21', 'spread': '21.40', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '26.31', 'spread': '20.39', 'groupId': 'OG000'}, {'value': '23.38', 'spread': '17.00', 'groupId': 'OG001'}, {'value': '13.71', 'spread': '10.58', 'groupId': 'OG002'}, {'value': '14.86', 'spread': '12.28', 'groupId': 'OG003'}, {'value': '40.92', 'spread': '21.69', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 = very good and 100 = very bad.', 'unitOfMeasure': 'mm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Physician Global Assessment of Arthritis (PGA) at Week 1, 2, 4, 8 and 12/EOT', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 1 (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '-16.04', 'spread': '15.29', 'groupId': 'OG000'}, {'value': '-14.12', 'spread': '13.11', 'groupId': 'OG001'}, {'value': '-14.11', 'spread': '12.67', 'groupId': 'OG002'}, {'value': '-22.92', 'spread': '21.00', 'groupId': 'OG003'}, {'value': '-8.75', 'spread': '15.39', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '-22.33', 'spread': '18.70', 'groupId': 'OG000'}, {'value': '-18.93', 'spread': '18.12', 'groupId': 'OG001'}, {'value': '-24.78', 'spread': '16.65', 'groupId': 'OG002'}, {'value': '-30.16', 'spread': '20.74', 'groupId': 'OG003'}, {'value': '-13.69', 'spread': '18.05', 'groupId': 'OG004'}]}]}, {'title': 'Week 4 (n=27,26,27,24,25)', 'categories': [{'measurements': [{'value': '-25.07', 'spread': '25.23', 'groupId': 'OG000'}, {'value': '-28.23', 'spread': '17.91', 'groupId': 'OG001'}, {'value': '-34.70', 'spread': '18.49', 'groupId': 'OG002'}, {'value': '-34.83', 'spread': '19.77', 'groupId': 'OG003'}, {'value': '-9.36', 'spread': '20.67', 'groupId': 'OG004'}]}]}, {'title': 'Week 8 (n=26,25,26,23,24)', 'categories': [{'measurements': [{'value': '-35.88', 'spread': '23.06', 'groupId': 'OG000'}, {'value': '-35.72', 'spread': '15.68', 'groupId': 'OG001'}, {'value': '-41.46', 'spread': '17.19', 'groupId': 'OG002'}, {'value': '-42.17', 'spread': '19.26', 'groupId': 'OG003'}, {'value': '-16.63', 'spread': '23.24', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '-39.23', 'spread': '27.72', 'groupId': 'OG000'}, {'value': '-36.92', 'spread': '17.53', 'groupId': 'OG001'}, {'value': '-44.71', 'spread': '15.94', 'groupId': 'OG002'}, {'value': '-45.05', 'spread': '20.37', 'groupId': 'OG003'}, {'value': '-15.92', 'spread': '24.95', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 = very good and 100 = very bad.', 'unitOfMeasure': 'mm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Health Assessment Questionnaire-Disability Index (HAQ-DI)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Baseline (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '1.14', 'spread': '0.74', 'groupId': 'OG000'}, {'value': '1.29', 'spread': '0.64', 'groupId': 'OG001'}, {'value': '1.17', 'spread': '0.60', 'groupId': 'OG002'}, {'value': '1.16', 'spread': '0.58', 'groupId': 'OG003'}, {'value': '1.25', 'spread': '0.70', 'groupId': 'OG004'}]}]}, {'title': 'Week 1 (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '1.05', 'spread': '0.75', 'groupId': 'OG000'}, {'value': '1.23', 'spread': '0.66', 'groupId': 'OG001'}, {'value': '1.05', 'spread': '0.54', 'groupId': 'OG002'}, {'value': '0.85', 'spread': '0.54', 'groupId': 'OG003'}, {'value': '1.25', 'spread': '0.74', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '1.04', 'spread': '0.72', 'groupId': 'OG000'}, {'value': '1.12', 'spread': '0.66', 'groupId': 'OG001'}, {'value': '0.88', 'spread': '0.56', 'groupId': 'OG002'}, {'value': '0.79', 'spread': '0.50', 'groupId': 'OG003'}, {'value': '1.18', 'spread': '0.76', 'groupId': 'OG004'}]}]}, {'title': 'Week 4 (n=27,26,27,24,25)', 'categories': [{'measurements': [{'value': '0.94', 'spread': '0.74', 'groupId': 'OG000'}, {'value': '1.04', 'spread': '0.75', 'groupId': 'OG001'}, {'value': '0.79', 'spread': '0.55', 'groupId': 'OG002'}, {'value': '0.77', 'spread': '0.58', 'groupId': 'OG003'}, {'value': '1.07', 'spread': '0.70', 'groupId': 'OG004'}]}]}, {'title': 'Week 8 (n=26,25,27,23,24)', 'categories': [{'measurements': [{'value': '0.80', 'spread': '0.69', 'groupId': 'OG000'}, {'value': '0.96', 'spread': '0.78', 'groupId': 'OG001'}, {'value': '0.72', 'spread': '0.54', 'groupId': 'OG002'}, {'value': '0.64', 'spread': '0.53', 'groupId': 'OG003'}, {'value': '1.21', 'spread': '0.80', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '0.78', 'spread': '0.70', 'groupId': 'OG000'}, {'value': '0.81', 'spread': '0.73', 'groupId': 'OG001'}, {'value': '0.56', 'spread': '0.41', 'groupId': 'OG002'}, {'value': '0.59', 'spread': '0.54', 'groupId': 'OG003'}, {'value': '1.13', 'spread': '0.79', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 1, 2, 4, 8 and 12/EOT', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 1 (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '-0.08', 'spread': '0.29', 'groupId': 'OG000'}, {'value': '-0.11', 'spread': '0.37', 'groupId': 'OG001'}, {'value': '-0.12', 'spread': '0.18', 'groupId': 'OG002'}, {'value': '-0.31', 'spread': '0.39', 'groupId': 'OG003'}, {'value': '-0.00', 'spread': '0.19', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '-0.13', 'spread': '0.35', 'groupId': 'OG000'}, {'value': '-0.17', 'spread': '0.39', 'groupId': 'OG001'}, {'value': '-0.29', 'spread': '0.32', 'groupId': 'OG002'}, {'value': '-0.39', 'spread': '0.38', 'groupId': 'OG003'}, {'value': '-0.02', 'spread': '0.26', 'groupId': 'OG004'}]}]}, {'title': 'Week 4 (n=27,26,27,24,25)', 'categories': [{'measurements': [{'value': '-0.22', 'spread': '0.48', 'groupId': 'OG000'}, {'value': '-0.25', 'spread': '0.47', 'groupId': 'OG001'}, {'value': '-0.38', 'spread': '0.30', 'groupId': 'OG002'}, {'value': '-0.43', 'spread': '0.42', 'groupId': 'OG003'}, {'value': '-0.10', 'spread': '0.26', 'groupId': 'OG004'}]}]}, {'title': 'Week 8 (n=26,25,27,23,24)', 'categories': [{'measurements': [{'value': '-0.36', 'spread': '0.58', 'groupId': 'OG000'}, {'value': '-0.32', 'spread': '0.49', 'groupId': 'OG001'}, {'value': '-0.45', 'spread': '0.31', 'groupId': 'OG002'}, {'value': '-0.52', 'spread': '0.44', 'groupId': 'OG003'}, {'value': '0.03', 'spread': '0.40', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '-0.38', 'spread': '0.55', 'groupId': 'OG000'}, {'value': '-0.41', 'spread': '0.46', 'groupId': 'OG001'}, {'value': '-0.49', 'spread': '0.35', 'groupId': 'OG002'}, {'value': '-0.57', 'spread': '0.46', 'groupId': 'OG003'}, {'value': '-0.05', 'spread': '0.43', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'C-Reactive Protein (CRP)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Baseline (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '26.71', 'spread': '31.02', 'groupId': 'OG000'}, {'value': '27.63', 'spread': '26.00', 'groupId': 'OG001'}, {'value': '16.59', 'spread': '16.15', 'groupId': 'OG002'}, {'value': '20.03', 'spread': '21.22', 'groupId': 'OG003'}, {'value': '22.25', 'spread': '25.05', 'groupId': 'OG004'}]}]}, {'title': 'Week 1 (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '15.45', 'spread': '21.23', 'groupId': 'OG000'}, {'value': '13.22', 'spread': '16.89', 'groupId': 'OG001'}, {'value': '4.52', 'spread': '6.49', 'groupId': 'OG002'}, {'value': '3.29', 'spread': '4.91', 'groupId': 'OG003'}, {'value': '20.63', 'spread': '22.24', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '15.79', 'spread': '20.73', 'groupId': 'OG000'}, {'value': '10.34', 'spread': '14.03', 'groupId': 'OG001'}, {'value': '3.16', 'spread': '5.37', 'groupId': 'OG002'}, {'value': '2.15', 'spread': '3.43', 'groupId': 'OG003'}, {'value': '18.12', 'spread': '21.97', 'groupId': 'OG004'}]}]}, {'title': 'Week 4 (n=27,26,27,24,25)', 'categories': [{'measurements': [{'value': '14.33', 'spread': '21.04', 'groupId': 'OG000'}, {'value': '9.59', 'spread': '14.22', 'groupId': 'OG001'}, {'value': '2.35', 'spread': '3.36', 'groupId': 'OG002'}, {'value': '2.40', 'spread': '5.13', 'groupId': 'OG003'}, {'value': '17.24', 'spread': '18.87', 'groupId': 'OG004'}]}]}, {'title': 'Week 8 (n=26,25,27,23,24)', 'categories': [{'measurements': [{'value': '13.82', 'spread': '22.16', 'groupId': 'OG000'}, {'value': '4.19', 'spread': '5.31', 'groupId': 'OG001'}, {'value': '4.18', 'spread': '12.36', 'groupId': 'OG002'}, {'value': '10.72', 'spread': '23.02', 'groupId': 'OG003'}, {'value': '15.29', 'spread': '16.50', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '12.04', 'spread': '21.23', 'groupId': 'OG000'}, {'value': '8.78', 'spread': '17.44', 'groupId': 'OG001'}, {'value': '2.98', 'spread': '8.72', 'groupId': 'OG002'}, {'value': '7.00', 'spread': '16.05', 'groupId': 'OG003'}, {'value': '17.37', 'spread': '25.30', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per liter (mg/L) to 10 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.', 'unitOfMeasure': 'mg/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in C-Reactive Protein (CRP) at Week 1, 2, 4, 8 and 12/EOT', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 1 (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '-11.26', 'spread': '14.29', 'groupId': 'OG000'}, {'value': '-15.37', 'spread': '20.41', 'groupId': 'OG001'}, {'value': '-12.07', 'spread': '11.50', 'groupId': 'OG002'}, {'value': '-16.75', 'spread': '19.28', 'groupId': 'OG003'}, {'value': '-1.62', 'spread': '11.47', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '-11.83', 'spread': '16.03', 'groupId': 'OG000'}, {'value': '-17.29', 'spread': '20.63', 'groupId': 'OG001'}, {'value': '-13.43', 'spread': '12.71', 'groupId': 'OG002'}, {'value': '-18.54', 'spread': '21.03', 'groupId': 'OG003'}, {'value': '-2.38', 'spread': '16.85', 'groupId': 'OG004'}]}]}, {'title': 'Week 4 (n=27,26,27,24,25)', 'categories': [{'measurements': [{'value': '-13.29', 'spread': '20.00', 'groupId': 'OG000'}, {'value': '-18.35', 'spread': '22.09', 'groupId': 'OG001'}, {'value': '-14.24', 'spread': '13.90', 'groupId': 'OG002'}, {'value': '-17.31', 'spread': '21.16', 'groupId': 'OG003'}, {'value': '-3.26', 'spread': '16.48', 'groupId': 'OG004'}]}]}, {'title': 'Week 8 (n=26,25,27,23,24)', 'categories': [{'measurements': [{'value': '-14.66', 'spread': '22.72', 'groupId': 'OG000'}, {'value': '-22.90', 'spread': '24.20', 'groupId': 'OG001'}, {'value': '-12.41', 'spread': '16.40', 'groupId': 'OG002'}, {'value': '-9.19', 'spread': '23.29', 'groupId': 'OG003'}, {'value': '-5.83', 'spread': '16.73', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '-16.43', 'spread': '27.15', 'groupId': 'OG000'}, {'value': '-17.89', 'spread': '28.20', 'groupId': 'OG001'}, {'value': '-10.49', 'spread': '14.72', 'groupId': 'OG002'}, {'value': '-14.10', 'spread': '22.34', 'groupId': 'OG003'}, {'value': '-3.75', 'spread': '19.97', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per liter (mg/L) to 10 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.', 'unitOfMeasure': 'mg/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Numeric Index of American College of Rheumatology Response (ACR-n)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 1', 'categories': [{'measurements': [{'value': '4.80', 'spread': '32.73', 'groupId': 'OG000'}, {'value': '6.06', 'spread': '20.00', 'groupId': 'OG001'}, {'value': '10.60', 'spread': '19.13', 'groupId': 'OG002'}, {'value': '10.73', 'spread': '42.87', 'groupId': 'OG003'}, {'value': '-11.08', 'spread': '21.61', 'groupId': 'OG004'}]}]}, {'title': 'Week 2', 'categories': [{'measurements': [{'value': '8.74', 'spread': '28.66', 'groupId': 'OG000'}, {'value': '17.43', 'spread': '25.30', 'groupId': 'OG001'}, {'value': '30.61', 'spread': '26.21', 'groupId': 'OG002'}, {'value': '25.15', 'spread': '28.64', 'groupId': 'OG003'}, {'value': '-8.84', 'spread': '26.69', 'groupId': 'OG004'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '14.67', 'spread': '38.45', 'groupId': 'OG000'}, {'value': '23.83', 'spread': '32.99', 'groupId': 'OG001'}, {'value': '40.88', 'spread': '26.07', 'groupId': 'OG002'}, {'value': '37.08', 'spread': '25.42', 'groupId': 'OG003'}, {'value': '-23.54', 'spread': '51.98', 'groupId': 'OG004'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '30.40', 'spread': '33.10', 'groupId': 'OG000'}, {'value': '31.64', 'spread': '33.87', 'groupId': 'OG001'}, {'value': '56.76', 'spread': '24.53', 'groupId': 'OG002'}, {'value': '45.62', 'spread': '29.46', 'groupId': 'OG003'}, {'value': '-18.74', 'spread': '62.37', 'groupId': 'OG004'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '30.26', 'spread': '35.83', 'groupId': 'OG000'}, {'value': '34.64', 'spread': '48.37', 'groupId': 'OG001'}, {'value': '60.16', 'spread': '24.26', 'groupId': 'OG002'}, {'value': '52.08', 'spread': '32.22', 'groupId': 'OG003'}, {'value': '-11.19', 'spread': '38.76', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 1, 2, 4, 8, 12/EOT', 'description': "ACR-n = calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study medication. Missing values were imputed using LOCF method.'}, {'type': 'SECONDARY', 'title': 'Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '1708.31', 'spread': '2458.38', 'groupId': 'OG000'}, {'value': '2096.79', 'spread': '2355.96', 'groupId': 'OG001'}, {'value': '3685.71', 'spread': '1721.44', 'groupId': 'OG002'}, {'value': '3124.40', 'spread': '2011.19', 'groupId': 'OG003'}, {'value': '-1346.24', 'spread': '2995.11', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline up to Week 12', 'description': "ACR-n = calculated for each participant by taking lowest percentage improvement in (1) swollen joint count or (2) tender joint count or (3) the median of remaining 5 components of ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The AUC for ACR-n is measure of the area under the curve of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute AUC.", 'unitOfMeasure': 'units on a scale*weeks', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all randomized participants who received at least 1 dose of study medication. Missing values were imputed using LOCF method.'}, {'type': 'SECONDARY', 'title': 'Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Baseline (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '5.03', 'spread': '0.68', 'groupId': 'OG000'}, {'value': '5.13', 'spread': '0.94', 'groupId': 'OG001'}, {'value': '5.00', 'spread': '0.96', 'groupId': 'OG002'}, {'value': '4.94', 'spread': '1.01', 'groupId': 'OG003'}, {'value': '4.90', 'spread': '0.87', 'groupId': 'OG004'}]}]}, {'title': 'Week 1 (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '4.30', 'spread': '0.86', 'groupId': 'OG000'}, {'value': '4.30', 'spread': '1.10', 'groupId': 'OG001'}, {'value': '4.09', 'spread': '1.28', 'groupId': 'OG002'}, {'value': '3.74', 'spread': '0.93', 'groupId': 'OG003'}, {'value': '4.61', 'spread': '1.08', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '4.23', 'spread': '0.95', 'groupId': 'OG000'}, {'value': '3.95', 'spread': '1.18', 'groupId': 'OG001'}, {'value': '3.46', 'spread': '1.25', 'groupId': 'OG002'}, {'value': '3.25', 'spread': '1.01', 'groupId': 'OG003'}, {'value': '4.43', 'spread': '1.11', 'groupId': 'OG004'}]}]}, {'title': 'Week 4 (n=27,26,27,24,25)', 'categories': [{'measurements': [{'value': '3.96', 'spread': '1.13', 'groupId': 'OG000'}, {'value': '3.63', 'spread': '1.05', 'groupId': 'OG001'}, {'value': '3.21', 'spread': '1.27', 'groupId': 'OG002'}, {'value': '2.80', 'spread': '0.94', 'groupId': 'OG003'}, {'value': '4.56', 'spread': '1.15', 'groupId': 'OG004'}]}]}, {'title': 'Week 8 (n=26,25,26,23,24)', 'categories': [{'measurements': [{'value': '3.43', 'spread': '1.03', 'groupId': 'OG000'}, {'value': '3.03', 'spread': '1.10', 'groupId': 'OG001'}, {'value': '2.77', 'spread': '0.97', 'groupId': 'OG002'}, {'value': '2.52', 'spread': '0.96', 'groupId': 'OG003'}, {'value': '4.31', 'spread': '1.21', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '3.21', 'spread': '1.05', 'groupId': 'OG000'}, {'value': '3.14', 'spread': '1.27', 'groupId': 'OG001'}, {'value': '2.55', 'spread': '0.90', 'groupId': 'OG002'}, {'value': '2.14', 'spread': '0.61', 'groupId': 'OG003'}, {'value': '4.15', 'spread': '1.36', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (=\\<) 3.2 implied low disease activity, \\>3.2 to 5.1 implied moderate to high disease activity and \\<2.6 implied remission.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Baseline (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '6.11', 'spread': '0.79', 'groupId': 'OG000'}, {'value': '6.06', 'spread': '1.04', 'groupId': 'OG001'}, {'value': '6.02', 'spread': '1.03', 'groupId': 'OG002'}, {'value': '5.86', 'spread': '0.95', 'groupId': 'OG003'}, {'value': '5.86', 'spread': '0.96', 'groupId': 'OG004'}]}]}, {'title': 'Week 1 (n=28,26,27,26,28)', 'categories': [{'measurements': [{'value': '5.42', 'spread': '0.98', 'groupId': 'OG000'}, {'value': '5.33', 'spread': '1.22', 'groupId': 'OG001'}, {'value': '5.09', 'spread': '1.34', 'groupId': 'OG002'}, {'value': '4.88', 'spread': '1.08', 'groupId': 'OG003'}, {'value': '5.46', 'spread': '1.11', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '5.29', 'spread': '1.07', 'groupId': 'OG000'}, {'value': '5.03', 'spread': '1.36', 'groupId': 'OG001'}, {'value': '4.48', 'spread': '1.37', 'groupId': 'OG002'}, {'value': '4.28', 'spread': '1.04', 'groupId': 'OG003'}, {'value': '5.34', 'spread': '1.24', 'groupId': 'OG004'}]}]}, {'title': 'Week 4 (n=27,26,27,24,25)', 'categories': [{'measurements': [{'value': '5.00', 'spread': '1.04', 'groupId': 'OG000'}, {'value': '4.54', 'spread': '1.29', 'groupId': 'OG001'}, {'value': '4.03', 'spread': '1.43', 'groupId': 'OG002'}, {'value': '3.72', 'spread': '1.13', 'groupId': 'OG003'}, {'value': '5.49', 'spread': '1.29', 'groupId': 'OG004'}]}]}, {'title': 'Week 8 (n=26,25,26,23,24)', 'categories': [{'measurements': [{'value': '4.37', 'spread': '1.05', 'groupId': 'OG000'}, {'value': '4.00', 'spread': '1.34', 'groupId': 'OG001'}, {'value': '3.49', 'spread': '1.21', 'groupId': 'OG002'}, {'value': '3.13', 'spread': '1.12', 'groupId': 'OG003'}, {'value': '5.22', 'spread': '1.42', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '4.07', 'spread': '0.99', 'groupId': 'OG000'}, {'value': '3.90', 'spread': '1.36', 'groupId': 'OG001'}, {'value': '3.13', 'spread': '0.99', 'groupId': 'OG002'}, {'value': '2.83', 'spread': '0.99', 'groupId': 'OG003'}, {'value': '5.07', 'spread': '1.47', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': "DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour \\[mm/hour\\]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (=\\<) 3.2 implied low disease activity, greater than (\\>) 3.2 to 5.1 implied moderate to high disease activity and less than (\\<) 2.6=remission.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': '36-Item Short-Form Health Survey (SF-36)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Baseline:Physical functioning (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '37.87', 'spread': '9.10', 'groupId': 'OG000'}, {'value': '37.94', 'spread': '9.37', 'groupId': 'OG001'}, {'value': '38.87', 'spread': '10.41', 'groupId': 'OG002'}, {'value': '40.93', 'spread': '9.47', 'groupId': 'OG003'}, {'value': '38.69', 'spread': '9.80', 'groupId': 'OG004'}]}]}, {'title': 'Baseline:Role Physical (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '39.27', 'spread': '11.83', 'groupId': 'OG000'}, {'value': '41.43', 'spread': '13.22', 'groupId': 'OG001'}, {'value': '44.25', 'spread': '10.25', 'groupId': 'OG002'}, {'value': '45.64', 'spread': '13.33', 'groupId': 'OG003'}, {'value': '42.77', 'spread': '11.69', 'groupId': 'OG004'}]}]}, {'title': 'Baseline:Bodily Pain (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '37.27', 'spread': '7.89', 'groupId': 'OG000'}, {'value': '36.89', 'spread': '7.53', 'groupId': 'OG001'}, {'value': '38.59', 'spread': '8.44', 'groupId': 'OG002'}, {'value': '40.58', 'spread': '7.00', 'groupId': 'OG003'}, {'value': '36.81', 'spread': '9.61', 'groupId': 'OG004'}]}]}, {'title': 'Baseline:General Health (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '37.54', 'spread': '6.14', 'groupId': 'OG000'}, {'value': '37.56', 'spread': '7.53', 'groupId': 'OG001'}, {'value': '37.57', 'spread': '10.16', 'groupId': 'OG002'}, {'value': '38.87', 'spread': '8.25', 'groupId': 'OG003'}, {'value': '37.42', 'spread': '7.00', 'groupId': 'OG004'}]}]}, {'title': 'Baseline:Vitality (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '45.07', 'spread': '11.58', 'groupId': 'OG000'}, {'value': '46.31', 'spread': '10.49', 'groupId': 'OG001'}, {'value': '46.19', 'spread': '11.13', 'groupId': 'OG002'}, {'value': '46.69', 'spread': '9.86', 'groupId': 'OG003'}, {'value': '46.96', 'spread': '9.58', 'groupId': 'OG004'}]}]}, {'title': 'Baseline:Social Functioning (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '46.72', 'spread': '13.5', 'groupId': 'OG000'}, {'value': '42.71', 'spread': '13.21', 'groupId': 'OG001'}, {'value': '45.54', 'spread': '10.47', 'groupId': 'OG002'}, {'value': '46.78', 'spread': '11.82', 'groupId': 'OG003'}, {'value': '45.16', 'spread': '12.74', 'groupId': 'OG004'}]}]}, {'title': 'Baseline:Role-Emotional (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '40.61', 'spread': '13.00', 'groupId': 'OG000'}, {'value': '41.05', 'spread': '13.47', 'groupId': 'OG001'}, {'value': '45.37', 'spread': '10.33', 'groupId': 'OG002'}, {'value': '45.11', 'spread': '14.93', 'groupId': 'OG003'}, {'value': '44.91', 'spread': '13.13', 'groupId': 'OG004'}]}]}, {'title': 'Baseline:Mental Health (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '43.07', 'spread': '10.15', 'groupId': 'OG000'}, {'value': '44.27', 'spread': '9.12', 'groupId': 'OG001'}, {'value': '43.65', 'spread': '10.11', 'groupId': 'OG002'}, {'value': '46.97', 'spread': '10.98', 'groupId': 'OG003'}, {'value': '45.08', 'spread': '11.81', 'groupId': 'OG004'}]}]}, {'title': 'Baseline:Physical Component (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '37.16', 'spread': '7.71', 'groupId': 'OG000'}, {'value': '37.54', 'spread': '7.92', 'groupId': 'OG001'}, {'value': '38.75', 'spread': '8.59', 'groupId': 'OG002'}, {'value': '40.39', 'spread': '7.02', 'groupId': 'OG003'}, {'value': '37.35', 'spread': '8.56', 'groupId': 'OG004'}]}]}, {'title': 'Baseline:Mental Component (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '46.06', 'spread': '12.16', 'groupId': 'OG000'}, {'value': '45.81', 'spread': '11.86', 'groupId': 'OG001'}, {'value': '47.38', 'spread': '9.60', 'groupId': 'OG002'}, {'value': '48.48', 'spread': '11.72', 'groupId': 'OG003'}, {'value': '48.36', 'spread': '12.08', 'groupId': 'OG004'}]}]}, {'title': 'Week 12:Physical functioning (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '42.71', 'spread': '10.07', 'groupId': 'OG000'}, {'value': '43.27', 'spread': '9.69', 'groupId': 'OG001'}, {'value': '46.42', 'spread': '9.00', 'groupId': 'OG002'}, {'value': '47.51', 'spread': '9.86', 'groupId': 'OG003'}, {'value': '40.72', 'spread': '9.40', 'groupId': 'OG004'}]}]}, {'title': 'Week 12:Role Physical (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '44.61', 'spread': '10.39', 'groupId': 'OG000'}, {'value': '46.96', 'spread': '10.60', 'groupId': 'OG001'}, {'value': '50.73', 'spread': '7.19', 'groupId': 'OG002'}, {'value': '50.32', 'spread': '9.37', 'groupId': 'OG003'}, {'value': '44.81', 'spread': '10.21', 'groupId': 'OG004'}]}]}, {'title': 'Week 12:Bodily Pain (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '42.81', 'spread': '7.05', 'groupId': 'OG000'}, {'value': '44.58', 'spread': '8.93', 'groupId': 'OG001'}, {'value': '48.70', 'spread': '7.20', 'groupId': 'OG002'}, {'value': '49.94', 'spread': '8.45', 'groupId': 'OG003'}, {'value': '39.77', 'spread': '7.98', 'groupId': 'OG004'}]}]}, {'title': 'Week 12:General Health (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '42.08', 'spread': '7.07', 'groupId': 'OG000'}, {'value': '43.14', 'spread': '8.63', 'groupId': 'OG001'}, {'value': '45.03', 'spread': '7.76', 'groupId': 'OG002'}, {'value': '45.19', 'spread': '8.06', 'groupId': 'OG003'}, {'value': '37.78', 'spread': '8.03', 'groupId': 'OG004'}]}]}, {'title': 'Week 12:Vitality (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '50.53', 'spread': '10.27', 'groupId': 'OG000'}, {'value': '49.88', 'spread': '11.52', 'groupId': 'OG001'}, {'value': '53.65', 'spread': '11.24', 'groupId': 'OG002'}, {'value': '52.24', 'spread': '11.53', 'groupId': 'OG003'}, {'value': '48.71', 'spread': '11.20', 'groupId': 'OG004'}]}]}, {'title': 'Week 12:Social Functioning (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '48.46', 'spread': '10.37', 'groupId': 'OG000'}, {'value': '46.62', 'spread': '12.49', 'groupId': 'OG001'}, {'value': '51.85', 'spread': '7.36', 'groupId': 'OG002'}, {'value': '52.43', 'spread': '8.20', 'groupId': 'OG003'}, {'value': '47.99', 'spread': '12.12', 'groupId': 'OG004'}]}]}, {'title': 'Week 12:Role-Emotional (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '47.51', 'spread': '8.64', 'groupId': 'OG000'}, {'value': '46.16', 'spread': '12.08', 'groupId': 'OG001'}, {'value': '47.78', 'spread': '10.12', 'groupId': 'OG002'}, {'value': '48.47', 'spread': '9.83', 'groupId': 'OG003'}, {'value': '44.70', 'spread': '12.15', 'groupId': 'OG004'}]}]}, {'title': 'Week 12:Mental Health (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '50.22', 'spread': '7.96', 'groupId': 'OG000'}, {'value': '47.90', 'spread': '11.87', 'groupId': 'OG001'}, {'value': '51.53', 'spread': '7.33', 'groupId': 'OG002'}, {'value': '49.07', 'spread': '12.51', 'groupId': 'OG003'}, {'value': '46.25', 'spread': '13.81', 'groupId': 'OG004'}]}]}, {'title': 'Week 12:Physical Component (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '41.21', 'spread': '9.42', 'groupId': 'OG000'}, {'value': '43.87', 'spread': '7.75', 'groupId': 'OG001'}, {'value': '47.27', 'spread': '6.61', 'groupId': 'OG002'}, {'value': '48.39', 'spread': '7.18', 'groupId': 'OG003'}, {'value': '39.77', 'spread': '6.59', 'groupId': 'OG004'}]}]}, {'title': 'Week 12:Mental Component (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '51.90', 'spread': '8.68', 'groupId': 'OG000'}, {'value': '48.93', 'spread': '13.44', 'groupId': 'OG001'}, {'value': '52.07', 'spread': '8.99', 'groupId': 'OG002'}, {'value': '50.68', 'spread': '10.10', 'groupId': 'OG003'}, {'value': '49.00', 'spread': '13.09', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 12/EOT', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Euro Quality of Life (EQ-5D)- Health State Profile Utility Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Baseline (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '0.55', 'spread': '0.26', 'groupId': 'OG000'}, {'value': '0.45', 'spread': '0.29', 'groupId': 'OG001'}, {'value': '0.58', 'spread': '0.24', 'groupId': 'OG002'}, {'value': '0.55', 'spread': '0.32', 'groupId': 'OG003'}, {'value': '0.51', 'spread': '0.33', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '0.65', 'spread': '0.23', 'groupId': 'OG000'}, {'value': '0.70', 'spread': '0.27', 'groupId': 'OG001'}, {'value': '0.79', 'spread': '0.13', 'groupId': 'OG002'}, {'value': '0.78', 'spread': '0.28', 'groupId': 'OG003'}, {'value': '0.59', 'spread': '0.27', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 12/EOT', 'description': 'EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Medical Outcome Study- Sleep Scale (MOS-SS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Baseline: SPS (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '27.38', 'spread': '11.42', 'groupId': 'OG000'}, {'value': '27.41', 'spread': '14.36', 'groupId': 'OG001'}, {'value': '29.38', 'spread': '17.54', 'groupId': 'OG002'}, {'value': '30.51', 'spread': '18.78', 'groupId': 'OG003'}, {'value': '23.93', 'spread': '12.57', 'groupId': 'OG004'}]}]}, {'title': 'Baseline: OSP (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '28.00', 'spread': '10.53', 'groupId': 'OG000'}, {'value': '27.55', 'spread': '12.40', 'groupId': 'OG001'}, {'value': '31.07', 'spread': '17.38', 'groupId': 'OG002'}, {'value': '31.28', 'spread': '18.60', 'groupId': 'OG003'}, {'value': '25.95', 'spread': '12.89', 'groupId': 'OG004'}]}]}, {'title': 'Baseline: Ade (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '52.86', 'spread': '24.47', 'groupId': 'OG000'}, {'value': '52.96', 'spread': '24.93', 'groupId': 'OG001'}, {'value': '49.63', 'spread': '27.80', 'groupId': 'OG002'}, {'value': '51.54', 'spread': '26.64', 'groupId': 'OG003'}, {'value': '58.57', 'spread': '27.98', 'groupId': 'OG004'}]}]}, {'title': 'Baseline: ASOB (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '3.57', 'spread': '9.51', 'groupId': 'OG000'}, {'value': '4.44', 'spread': '10.13', 'groupId': 'OG001'}, {'value': '8.15', 'spread': '22.37', 'groupId': 'OG002'}, {'value': '10.00', 'spread': '14.14', 'groupId': 'OG003'}, {'value': '3.57', 'spread': '7.80', 'groupId': 'OG004'}]}]}, {'title': 'Baseline: SD (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '24.06', 'spread': '17.70', 'groupId': 'OG000'}, {'value': '23.84', 'spread': '21.10', 'groupId': 'OG001'}, {'value': '25.28', 'spread': '20.95', 'groupId': 'OG002'}, {'value': '25.77', 'spread': '21.45', 'groupId': 'OG003'}, {'value': '21.43', 'spread': '16.66', 'groupId': 'OG004'}]}]}, {'title': 'Baseline: Opt (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '0.61', 'spread': '0.50', 'groupId': 'OG000'}, {'value': '0.30', 'spread': '0.47', 'groupId': 'OG001'}, {'value': '0.41', 'spread': '0.50', 'groupId': 'OG002'}, {'value': '0.42', 'spread': '0.50', 'groupId': 'OG003'}, {'value': '0.39', 'spread': '0.50', 'groupId': 'OG004'}]}]}, {'title': 'Baseline: Qua (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '6.61', 'spread': '1.10', 'groupId': 'OG000'}, {'value': '6.37', 'spread': '1.45', 'groupId': 'OG001'}, {'value': '6.30', 'spread': '0.87', 'groupId': 'OG002'}, {'value': '6.38', 'spread': '1.27', 'groupId': 'OG003'}, {'value': '6.43', 'spread': '1.29', 'groupId': 'OG004'}]}]}, {'title': 'Baseline: Sno (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '25.00', 'spread': '27.01', 'groupId': 'OG000'}, {'value': '32.59', 'spread': '34.26', 'groupId': 'OG001'}, {'value': '31.85', 'spread': '31.99', 'groupId': 'OG002'}, {'value': '23.08', 'spread': '29.77', 'groupId': 'OG003'}, {'value': '31.43', 'spread': '29.53', 'groupId': 'OG004'}]}]}, {'title': 'Baseline: Som (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '29.05', 'spread': '19.13', 'groupId': 'OG000'}, {'value': '28.64', 'spread': '17.81', 'groupId': 'OG001'}, {'value': '34.57', 'spread': '25.22', 'groupId': 'OG002'}, {'value': '32.05', 'spread': '22.86', 'groupId': 'OG003'}, {'value': '31.90', 'spread': '19.49', 'groupId': 'OG004'}]}]}, {'title': 'Week 2: SPS (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '27.04', 'spread': '11.52', 'groupId': 'OG000'}, {'value': '25.19', 'spread': '12.55', 'groupId': 'OG001'}, {'value': '22.10', 'spread': '16.28', 'groupId': 'OG002'}, {'value': '27.87', 'spread': '19.41', 'groupId': 'OG003'}, {'value': '26.67', 'spread': '16.49', 'groupId': 'OG004'}]}]}, {'title': 'Week 2: OSP (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '27.61', 'spread': '10.05', 'groupId': 'OG000'}, {'value': '25.62', 'spread': '12.35', 'groupId': 'OG001'}, {'value': '22.78', 'spread': '15.29', 'groupId': 'OG002'}, {'value': '27.47', 'spread': '18.67', 'groupId': 'OG003'}, {'value': '27.74', 'spread': '15.79', 'groupId': 'OG004'}]}]}, {'title': 'Week 2: Ade (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '53.33', 'spread': '23.86', 'groupId': 'OG000'}, {'value': '54.81', 'spread': '22.42', 'groupId': 'OG001'}, {'value': '64.07', 'spread': '27.49', 'groupId': 'OG002'}, {'value': '51.20', 'spread': '29.48', 'groupId': 'OG003'}, {'value': '55.38', 'spread': '25.33', 'groupId': 'OG004'}]}]}, {'title': 'Week 2: ASOB (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '5.93', 'spread': '16.47', 'groupId': 'OG000'}, {'value': '4.44', 'spread': '8.47', 'groupId': 'OG001'}, {'value': '8.15', 'spread': '20.95', 'groupId': 'OG002'}, {'value': '7.20', 'spread': '12.75', 'groupId': 'OG003'}, {'value': '4.62', 'spread': '11.74', 'groupId': 'OG004'}]}]}, {'title': 'Week 2: SD (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '22.31', 'spread': '14.11', 'groupId': 'OG000'}, {'value': '19.68', 'spread': '19.19', 'groupId': 'OG001'}, {'value': '17.92', 'spread': '14.88', 'groupId': 'OG002'}, {'value': '21.40', 'spread': '21.39', 'groupId': 'OG003'}, {'value': '21.44', 'spread': '18.22', 'groupId': 'OG004'}]}]}, {'title': 'Week 2: Opt (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '0.63', 'spread': '0.49', 'groupId': 'OG000'}, {'value': '0.44', 'spread': '0.51', 'groupId': 'OG001'}, {'value': '0.56', 'spread': '0.51', 'groupId': 'OG002'}, {'value': '0.52', 'spread': '0.51', 'groupId': 'OG003'}, {'value': '0.38', 'spread': '0.50', 'groupId': 'OG004'}]}]}, {'title': 'Week 2: Qua (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '6.70', 'spread': '0.82', 'groupId': 'OG000'}, {'value': '6.52', 'spread': '1.16', 'groupId': 'OG001'}, {'value': '6.70', 'spread': '1.14', 'groupId': 'OG002'}, {'value': '6.84', 'spread': '1.25', 'groupId': 'OG003'}, {'value': '6.50', 'spread': '1.24', 'groupId': 'OG004'}]}]}, {'title': 'Week 2: Sno (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '25.19', 'spread': '26.94', 'groupId': 'OG000'}, {'value': '25.19', 'spread': '22.60', 'groupId': 'OG001'}, {'value': '23.70', 'spread': '29.89', 'groupId': 'OG002'}, {'value': '17.60', 'spread': '24.71', 'groupId': 'OG003'}, {'value': '30.00', 'spread': '34.06', 'groupId': 'OG004'}]}]}, {'title': 'Week 2: Som (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '30.37', 'spread': '18.05', 'groupId': 'OG000'}, {'value': '29.14', 'spread': '19.93', 'groupId': 'OG001'}, {'value': '27.90', 'spread': '23.46', 'groupId': 'OG002'}, {'value': '26.13', 'spread': '23.88', 'groupId': 'OG003'}, {'value': '35.64', 'spread': '20.65', 'groupId': 'OG004'}]}]}, {'title': 'Week 12: SPS (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '24.49', 'spread': '10.83', 'groupId': 'OG000'}, {'value': '24.17', 'spread': '14.22', 'groupId': 'OG001'}, {'value': '23.89', 'spread': '11.78', 'groupId': 'OG002'}, {'value': '25.56', 'spread': '14.47', 'groupId': 'OG003'}, {'value': '28.75', 'spread': '14.24', 'groupId': 'OG004'}]}]}, {'title': 'Week 12: OSP (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '25.19', 'spread': '10.33', 'groupId': 'OG000'}, {'value': '24.19', 'spread': '13.39', 'groupId': 'OG001'}, {'value': '23.08', 'spread': '10.74', 'groupId': 'OG002'}, {'value': '24.52', 'spread': '14.29', 'groupId': 'OG003'}, {'value': '29.56', 'spread': '13.10', 'groupId': 'OG004'}]}]}, {'title': 'Week 12: Ade (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '60.00', 'spread': '22.63', 'groupId': 'OG000'}, {'value': '58.75', 'spread': '26.75', 'groupId': 'OG001'}, {'value': '51.67', 'spread': '24.08', 'groupId': 'OG002'}, {'value': '53.33', 'spread': '23.94', 'groupId': 'OG003'}, {'value': '54.17', 'spread': '19.54', 'groupId': 'OG004'}]}]}, {'title': 'Week 12: ASOB (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '6.92', 'spread': '13.79', 'groupId': 'OG000'}, {'value': '9.17', 'spread': '14.42', 'groupId': 'OG001'}, {'value': '5.00', 'spread': '10.63', 'groupId': 'OG002'}, {'value': '3.81', 'spread': '8.05', 'groupId': 'OG003'}, {'value': '10.00', 'spread': '20.43', 'groupId': 'OG004'}]}]}, {'title': 'Week 12: SD (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '20.34', 'spread': '13.42', 'groupId': 'OG000'}, {'value': '19.22', 'spread': '18.43', 'groupId': 'OG001'}, {'value': '14.43', 'spread': '10.52', 'groupId': 'OG002'}, {'value': '18.99', 'spread': '19.05', 'groupId': 'OG003'}, {'value': '21.09', 'spread': '16.56', 'groupId': 'OG004'}]}]}, {'title': 'Week 12: Opt (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '0.54', 'spread': '0.51', 'groupId': 'OG000'}, {'value': '0.38', 'spread': '0.49', 'groupId': 'OG001'}, {'value': '0.38', 'spread': '0.49', 'groupId': 'OG002'}, {'value': '0.48', 'spread': '0.51', 'groupId': 'OG003'}, {'value': '0.46', 'spread': '0.51', 'groupId': 'OG004'}]}]}, {'title': 'Week 12: Qua (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '6.35', 'spread': '1.20', 'groupId': 'OG000'}, {'value': '6.54', 'spread': '1.28', 'groupId': 'OG001'}, {'value': '6.38', 'spread': '0.97', 'groupId': 'OG002'}, {'value': '6.71', 'spread': '1.38', 'groupId': 'OG003'}, {'value': '6.54', 'spread': '1.53', 'groupId': 'OG004'}]}]}, {'title': 'Week 12: Sno (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '24.62', 'spread': '22.13', 'groupId': 'OG000'}, {'value': '21.67', 'spread': '22.78', 'groupId': 'OG001'}, {'value': '29.17', 'spread': '32.83', 'groupId': 'OG002'}, {'value': '13.33', 'spread': '20.33', 'groupId': 'OG003'}, {'value': '33.33', 'spread': '31.02', 'groupId': 'OG004'}]}]}, {'title': 'Week 12: Som (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '30.26', 'spread': '18.59', 'groupId': 'OG000'}, {'value': '25.28', 'spread': '20.99', 'groupId': 'OG001'}, {'value': '25.28', 'spread': '16.33', 'groupId': 'OG002'}, {'value': '24.13', 'spread': '23.24', 'groupId': 'OG003'}, {'value': '40.28', 'spread': '19.51', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 12/EOT', 'description': 'Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales:sleep disturbance(SD),snoring(Sno),awakened short of breath(ASOB),sleep adequacy(Ade),somnolence(Som)(range:0-100);sleep quantity(Qua)(range:0-24),optimal(Opt) sleep(yes:1,no:0),9 item index measures of sleep disturbance provide composite scores:sleep problem summary(SPS),overall SP(OSP).Except Ade,Opt,Qua,higher scores=more impairment.Scores transformed(actual raw score(RS) minus lowest possible score divided by possible RS range\\*100);total score range:0-100;higher score=more intensity of attribute.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}, {'type': 'SECONDARY', 'title': 'Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Baseline (n=28,27,27,26,28)', 'categories': [{'measurements': [{'value': '34.25', 'spread': '10.45', 'groupId': 'OG000'}, {'value': '33.37', 'spread': '11.03', 'groupId': 'OG001'}, {'value': '34.48', 'spread': '9.99', 'groupId': 'OG002'}, {'value': '36.85', 'spread': '9.43', 'groupId': 'OG003'}, {'value': '37.07', 'spread': '9.87', 'groupId': 'OG004'}]}]}, {'title': 'Week 2 (n=27,27,27,25,26)', 'categories': [{'measurements': [{'value': '36.78', 'spread': '8.64', 'groupId': 'OG000'}, {'value': '36.48', 'spread': '9.72', 'groupId': 'OG001'}, {'value': '39.30', 'spread': '10.56', 'groupId': 'OG002'}, {'value': '40.80', 'spread': '6.87', 'groupId': 'OG003'}, {'value': '37.38', 'spread': '10.31', 'groupId': 'OG004'}]}]}, {'title': 'Week 12 (n=26,24,24,21,24)', 'categories': [{'measurements': [{'value': '39.35', 'spread': '7.47', 'groupId': 'OG000'}, {'value': '37.96', 'spread': '9.95', 'groupId': 'OG001'}, {'value': '42.79', 'spread': '8.47', 'groupId': 'OG002'}, {'value': '40.76', 'spread': '10.65', 'groupId': 'OG003'}, {'value': '36.46', 'spread': '9.93', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 2, 12/EOT', 'description': "FACIT-F is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all randomized participants who received at least 1 dose of study medication. 'n' = number of participants who were evaluable at specific time points for each arm group, respectively."}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'FG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'FG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'FG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'FG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '28'}, {'groupId': 'FG001', 'numSubjects': '28'}, {'groupId': 'FG002', 'numSubjects': '28'}, {'groupId': 'FG003', 'numSubjects': '28'}, {'groupId': 'FG004', 'numSubjects': '28'}]}, {'type': 'Treated', 'achievements': [{'groupId': 'FG000', 'numSubjects': '28'}, {'groupId': 'FG001', 'numSubjects': '27'}, {'groupId': 'FG002', 'numSubjects': '27'}, {'groupId': 'FG003', 'numSubjects': '26'}, {'groupId': 'FG004', 'numSubjects': '28'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '26'}, {'groupId': 'FG001', 'numSubjects': '23'}, {'groupId': 'FG002', 'numSubjects': '23'}, {'groupId': 'FG003', 'numSubjects': '21'}, {'groupId': 'FG004', 'numSubjects': '23'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '5'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '7'}, {'groupId': 'FG004', 'numSubjects': '5'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '2'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}]}, {'type': 'Randomized but not treated', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'BG000'}, {'value': '27', 'groupId': 'BG001'}, {'value': '27', 'groupId': 'BG002'}, {'value': '26', 'groupId': 'BG003'}, {'value': '28', 'groupId': 'BG004'}, {'value': '136', 'groupId': 'BG005'}]}], 'groups': [{'id': 'BG000', 'title': 'CP-690,550 1 mg', 'description': 'CP-690,550 1 milligram (mg) tablet orally twice daily for 12 weeks.'}, {'id': 'BG001', 'title': 'CP-690,550 3 mg', 'description': 'CP-690,550 3 mg tablet orally twice daily for 12 weeks.'}, {'id': 'BG002', 'title': 'CP-690,550 5 mg', 'description': 'CP-690,550 5 mg tablet orally twice daily for 12 weeks.'}, {'id': 'BG003', 'title': 'CP-690,550 10 mg', 'description': 'CP-690,550 10 mg tablet orally twice daily for 12 weeks.'}, {'id': 'BG004', 'title': 'Placebo', 'description': 'Placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'BG005', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age Continuous', 'classes': [{'categories': [{'measurements': [{'value': '52.0', 'spread': '9.4', 'groupId': 'BG000'}, {'value': '53.3', 'spread': '12.1', 'groupId': 'BG001'}, {'value': '50.0', 'spread': '9.8', 'groupId': 'BG002'}, {'value': '50.6', 'spread': '10.0', 'groupId': 'BG003'}, {'value': '50.6', 'spread': '12.4', 'groupId': 'BG004'}, {'value': '51.3', 'spread': '10.7', 'groupId': 'BG005'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '21', 'groupId': 'BG000'}, {'value': '24', 'groupId': 'BG001'}, {'value': '22', 'groupId': 'BG002'}, {'value': '25', 'groupId': 'BG003'}, {'value': '25', 'groupId': 'BG004'}, {'value': '117', 'groupId': 'BG005'}]}, {'title': 'Male', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '19', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 140}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2008-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2012-12', 'dispFirstSubmitDate': '2009-04-06', 'completionDateStruct': {'date': '2008-09', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2012-12-16', 'studyFirstSubmitDate': '2008-01-17', 'dispFirstSubmitQcDate': '2009-10-21', 'resultsFirstSubmitDate': '2012-11-14', 'studyFirstSubmitQcDate': '2008-01-17', 'dispFirstPostDateStruct': {'date': '2009-10-23', 'type': 'ESTIMATED'}, 'lastUpdatePostDateStruct': {'date': '2013-01-25', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2012-12-16', 'studyFirstPostDateStruct': {'date': '2008-01-29', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2013-01-25', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2008-09', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12', 'timeFrame': 'Week 12', 'description': 'ACR20 response: greater than or equal to (\\>=) 20 percent (%) improvement in tender joint count (TJC); \\>= 20% improvement in swollen joint count (SJC); and \\>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP).'}], 'secondaryOutcomes': [{'measure': 'Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response', 'timeFrame': 'Week 1, 2, 4, 8', 'description': 'ACR20 response: \\>= 20% improvement in TJC; \\>= 20% improvement in SJC; and \\>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.'}, {'measure': 'Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response', 'timeFrame': 'Week 1, 2, 4, 8, 12/End of Treatment (EOT)', 'description': 'ACR50 response: \\>= 50% improvement in tender or swollen joint counts and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.'}, {'measure': 'Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response', 'timeFrame': 'Week 1, 2, 4, 8, 12/EOT', 'description': 'ACR70 response: \\>= 70% improvement in tender or swollen joint counts and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.'}, {'measure': 'Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response', 'timeFrame': 'Week 1, 2, 4, 8, 12/EOT', 'description': 'ACR90 response: \\>= 90% improvement in tender or swollen joint counts and 90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.'}, {'measure': 'Tender Joint Count (TJC)', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.'}, {'measure': 'Change From Baseline in Tender Joint Count (TJC) at Week 1, 2, 4, 8 and 12/EOT', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicates an improvement.'}, {'measure': 'Swollen Joint Count (SJC)', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.'}, {'measure': 'Change From Baseline in Swollen Joint Count (SJC) at Week 1, 2, 4, 8 and 12/EOT', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement.'}, {'measure': 'Patient Assessment of Arthritis Pain', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 = no pain and 100 = most severe pain.'}, {'measure': 'Change From Baseline in Patient Assessment of Arthritis Pain at Week 1, 2, 4, 8 and 12/EOT', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 = no pain and 100 = most severe pain.'}, {'measure': 'Patient Global Assessment (PtGA) of Arthritis', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 = very well and 100 = very poorly.'}, {'measure': 'Change From Baseline in Patient Global Assessment of Arthritis (PtGA) at Week 1, 2, 4, 8 and 12/EOT', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 = very well and 100 = very poorly.'}, {'measure': 'Physician Global Assessment (PGA) of Arthritis', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 = very good and 100 = very bad.'}, {'measure': 'Change From Baseline in Physician Global Assessment of Arthritis (PGA) at Week 1, 2, 4, 8 and 12/EOT', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 = very good and 100 = very bad.'}, {'measure': 'Health Assessment Questionnaire-Disability Index (HAQ-DI)', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.'}, {'measure': 'Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 1, 2, 4, 8 and 12/EOT', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.'}, {'measure': 'C-Reactive Protein (CRP)', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per liter (mg/L) to 10 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.'}, {'measure': 'Change From Baseline in C-Reactive Protein (CRP) at Week 1, 2, 4, 8 and 12/EOT', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per liter (mg/L) to 10 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.'}, {'measure': 'Numeric Index of American College of Rheumatology Response (ACR-n)', 'timeFrame': 'Week 1, 2, 4, 8, 12/EOT', 'description': "ACR-n = calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening."}, {'measure': 'Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve', 'timeFrame': 'Baseline up to Week 12', 'description': "ACR-n = calculated for each participant by taking lowest percentage improvement in (1) swollen joint count or (2) tender joint count or (3) the median of remaining 5 components of ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The AUC for ACR-n is measure of the area under the curve of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute AUC."}, {'measure': 'Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': 'DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (=\\<) 3.2 implied low disease activity, \\>3.2 to 5.1 implied moderate to high disease activity and \\<2.6 implied remission.'}, {'measure': 'Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])', 'timeFrame': 'Baseline, Week 1, 2, 4, 8, 12/EOT', 'description': "DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour \\[mm/hour\\]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (=\\<) 3.2 implied low disease activity, greater than (\\>) 3.2 to 5.1 implied moderate to high disease activity and less than (\\<) 2.6=remission."}, {'measure': '36-Item Short-Form Health Survey (SF-36)', 'timeFrame': 'Baseline, Week 12/EOT', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).'}, {'measure': 'Euro Quality of Life (EQ-5D)- Health State Profile Utility Score', 'timeFrame': 'Baseline, Week 12/EOT', 'description': 'EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.'}, {'measure': 'Medical Outcome Study- Sleep Scale (MOS-SS)', 'timeFrame': 'Baseline, Week 2, 12/EOT', 'description': 'Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales:sleep disturbance(SD),snoring(Sno),awakened short of breath(ASOB),sleep adequacy(Ade),somnolence(Som)(range:0-100);sleep quantity(Qua)(range:0-24),optimal(Opt) sleep(yes:1,no:0),9 item index measures of sleep disturbance provide composite scores:sleep problem summary(SPS),overall SP(OSP).Except Ade,Opt,Qua,higher scores=more impairment.Scores transformed(actual raw score(RS) minus lowest possible score divided by possible RS range\\*100);total score range:0-100;higher score=more intensity of attribute.'}, {'measure': 'Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale', 'timeFrame': 'Baseline, Week 2, 12/EOT', 'description': "FACIT-F is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status."}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Phase II MTX add-on study in Japan'], 'conditions': ['Arthritis, Rheumatoid']}, 'referencesModule': {'references': [{'pmid': '39192350', 'type': 'DERIVED', 'citation': 'Hetland ML, Strangfeld A, Bonfanti G, Soudis D, Deuring JJ, Edwards RA. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. Arthritis Res Ther. 2024 Aug 27;26(1):153. doi: 10.1186/s13075-024-03376-9.'}, {'pmid': '38958913', 'type': 'DERIVED', 'citation': 'Wright GC, Mysler E, Kwok K, Cadatal MJ, Germino R, Yndestad A, Kinch CD, Ogdie A. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.'}, {'pmid': '36931693', 'type': 'DERIVED', 'citation': 'Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.'}, {'pmid': '36601090', 'type': 'DERIVED', 'citation': 'Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.'}, {'pmid': '36600185', 'type': 'DERIVED', 'citation': 'Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.'}, {'pmid': '36526796', 'type': 'DERIVED', 'citation': 'Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.'}, {'pmid': '34870800', 'type': 'DERIVED', 'citation': 'Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.'}, {'pmid': '33127856', 'type': 'DERIVED', 'citation': 'Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395.'}, {'pmid': '32816215', 'type': 'DERIVED', 'citation': 'Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20.'}, {'pmid': '28941219', 'type': 'DERIVED', 'citation': 'Mariette X, Chen C, Biswas P, Kwok K, Boy MG. Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program. Arthritis Care Res (Hoboken). 2018 May;70(5):685-694. doi: 10.1002/acr.23421. Epub 2018 Apr 2.'}, {'pmid': '28143815', 'type': 'DERIVED', 'citation': 'Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.'}, {'pmid': '26275429', 'type': 'DERIVED', 'citation': 'Charles-Schoeman C, Burmester G, Nash P, Zerbini CA, Soma K, Kwok K, Hendrikx T, Bananis E, Fleischmann R. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2016 Jul;75(7):1293-301. doi: 10.1136/annrheumdis-2014-207178. Epub 2015 Aug 14.'}, {'pmid': '25047021', 'type': 'DERIVED', 'citation': 'Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, Soma K, Nduaka CI, Kwok K, Valdez H, Benda B, Riese R. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014 Nov;66(11):2924-37. doi: 10.1002/art.38779.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine the effectiveness and safety, over 3 months, of 4 dose regimens of CP-690,550, combined with methotrexate, for the treatment with active rheumatoid arthritis.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '20 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Active rheumatoid arthritis\n* Inadequate response to stably dosed methotrexate\n\nExclusion Criteria:\n\n* Current therapy with any DMARD or biologic other than methotrexate'}, 'identificationModule': {'nctId': 'NCT00603512', 'briefTitle': 'Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan', 'organization': {'class': 'INDUSTRY', 'fullName': 'Pfizer'}, 'officialTitle': 'A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Confirm Dose Responsiveness Following 12 Weeks of the Administration of CP-690,550 (4 Doses) or Placebo in Subjects With Active Rheumatoid Arthritis Inadequately Controlled With Methotrexate Alone', 'orgStudyIdInfo': {'id': 'A3921039'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'CP-690,550, 0mg', 'interventionNames': ['Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'CP-690,550, 10mg', 'interventionNames': ['Drug: CP-690,550']}, {'type': 'EXPERIMENTAL', 'label': 'CP-690,550, 1mg', 'interventionNames': ['Drug: CP-690,550']}, {'type': 'EXPERIMENTAL', 'label': 'CP-690,550, 3mg', 'interventionNames': ['Drug: CP-690,550']}, {'type': 'EXPERIMENTAL', 'label': 'CP-690,550, 5mg', 'interventionNames': ['Drug: CP-690,550']}], 'interventions': [{'name': 'Placebo', 'type': 'DRUG', 'description': '0 mg BID, 3 blinded tablets administered BID for 12 weeks', 'armGroupLabels': ['CP-690,550, 0mg']}, {'name': 'CP-690,550', 'type': 'DRUG', 'description': '10 mg BID, 3 blinded tablets administered BID for 12 weeks', 'armGroupLabels': ['CP-690,550, 10mg']}, {'name': 'CP-690,550', 'type': 'DRUG', 'description': '1 mg BID, 3 blinded tablets administered BID for 12 weeks', 'armGroupLabels': ['CP-690,550, 1mg']}, {'name': 'CP-690,550', 'type': 'DRUG', 'description': '3 mg BID, 3 blinded tablets administered BID for 12 weeks', 'armGroupLabels': ['CP-690,550, 3mg']}, {'name': 'CP-690,550', 'type': 'DRUG', 'description': '5 mg BID, 3 blinded tablets administered BID for 12 weeks', 'armGroupLabels': ['CP-690,550, 5mg']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Chiba', 'state': 'Chiba', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 35.6, 'lon': 140.11667}}, {'city': 'Fukuoka', 'state': 'Fukuoka', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 33.6, 'lon': 130.41667}}, {'city': 'Hitachi-shi', 'state': 'Ibaraki', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Sagamihara', 'state': 'Kanagawa', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 35.56707, 'lon': 139.24167}}, {'city': 'Yahatanishi-ku', 'state': 'Kitakyusyu', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Koushi', 'state': 'Kumamoto', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Sendai', 'state': 'Miyagi', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 38.26667, 'lon': 140.86667}}, {'city': 'Niigata', 'state': 'Niigata', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 37.92259, 'lon': 139.04125}}, {'city': 'Kawachi-Nagano', 'state': 'Osaka', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 34.44108, 'lon': 135.58283}}, {'city': 'Kawagoe-shi', 'state': 'Saitama', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Kitamoto', 'state': 'Saitama', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 36.03322, 'lon': 139.53775}}, {'city': 'Bunkyo-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Bunkyo-k', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Chiyoda-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Koto-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Meguro-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Musashimurayama-shi', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Shinjyuku-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}], 'overallOfficials': [{'name': 'Pfizer CT.gov Call Center', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Pfizer'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pfizer', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}